SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus

Key Takeaways SMMT reported a wider Q4 loss of 29 cents per share, with no revenues recorded in 2025.Summit Therapeutics boosted R&D 117% to advance ivonescimab across late-stage NSCLC studies.SMMT's FDA-accepted BLA for ivonescimab in NSCLC faces a decision by Nov. 14, 2026.Summit Therapeutics (SMMT) reported fourth-quarter 2025 loss per share of 29 cents, wider than the Zacks Consensus Estimate of 22 cents. In the year-ago period, the company had incurred a loss of 8 cents per share.The reported loss incl ...